Thoughts? I'm not concerned about it being rejected, but I'm curious how much is priced in at this point. I have seen numerous stocks sell off with actual FDA approval, but I'm not so sure about panel votes.
I don't think the panel vote is fully priced in. The peak revenue for Gattex can reach $350M excluding off-label uses. Multiply this with 5 you get a $1.75B market value. Gattex is now a slam dunk. Natpara is also a high possibility.
Based on most conservative predictions:
- Gattex approved
- no off-label use
- Natpara rejected
NPSP should still be a $1.75B company. This converts to about $20 per share. MM can manipulate this stock after panel vote just to buy cheap but this may be a $20 stock by year end.